1. Home
  2. SOTK vs ACRV Comparison

SOTK vs ACRV Comparison

Compare SOTK & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sono-Tek Corporation

SOTK

Sono-Tek Corporation

HOLD

Current Price

$5.49

Market Cap

73.7M

Sector

Technology

ML Signal

HOLD

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$1.96

Market Cap

67.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOTK
ACRV
Founded
1975
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
73.7M
67.2M
IPO Year
1995
2022

Fundamental Metrics

Financial Performance
Metric
SOTK
ACRV
Price
$5.49
$1.96
Analyst Decision
Hold
Buy
Analyst Count
1
4
Target Price
N/A
$11.67
AVG Volume (30 Days)
45.4K
415.4K
Earning Date
05-27-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
37.50
15.13
EPS
0.05
N/A
Revenue
$20,909,315.00
N/A
Revenue This Year
$4.02
N/A
Revenue Next Year
$10.95
$568.17
P/E Ratio
$110.40
N/A
Revenue Growth
1.97
N/A
52 Week Low
$3.23
$1.20
52 Week High
$6.24
$3.56

Technical Indicators

Market Signals
Indicator
SOTK
ACRV
Relative Strength Index (RSI) 55.03 65.74
Support Level $3.79 $1.62
Resistance Level $5.72 $2.02
Average True Range (ATR) 0.47 0.12
MACD -0.00 0.05
Stochastic Oscillator 49.17 74.07

Price Performance

Historical Comparison
SOTK
ACRV

About SOTK Sono-Tek Corporation

Sono-Tek Corp design and manufacture of ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial and emerging research & development/other markets. The company design and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with strong applications engineering knowledge, to assist its customers in achieving their desired coating solutions.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

Share on Social Networks: